摘要
目的:通过系统综述和药物经济学的相关方法对奥美拉唑三联疗法与埃索美拉唑三联疗法治疗消化性溃疡的有效性、安全性和经济性进行评价,为临床治疗消化性溃疡用药提供参考和建议;方法:通过Meta分析比较两种治疗方案的疗效和安全性,构建决策树模型,对2种治疗方案治疗消化性溃疡进行成本效果分析,并进行单因素敏感性分析和概率敏感性分析。结果:Meta分析结果显示,在疗效方面,埃索美拉唑三联疗法略优于奥美拉唑三联疗法(幽门螺杆菌根除率:RR=0.93,P=0.03),安全性方面,2种方案无显著性差异(不良反应发生率:RR=0.91,P=0.19),均具有较好的安全性;药物经济学评价结果显示,相比于奥美拉唑三联疗法,埃索美拉唑三联疗法的ICER值为2 609.00元,敏感性分析结果与基础分析结果基本一致,说明基础分析结果较为稳健。结论:埃索美拉唑三联疗法治疗消化性溃疡的疗效略优于奥美拉唑三联疗法,但相比于奥美拉唑三联疗法,埃索美拉唑三联疗法的ICER值过高,因此奥美拉唑三联疗法治疗消化性溃疡更具有经济性。
OBJECTIVE To evaluate the efficacy, the safety, the cost-effectiveness and economics of esomeprazole-based triple therapy versus omeprazole-based triple therapy for patients with peptic ulcer by systematic review and pharmacoeconomicsto provide reference and recommendations for the clinical treatment of peptic ulcer medication. METHODS Meta-analysis was used to compare the efficacy and safety of the two treatment options, and evaluate the cost-effectiveness by establishing a decision tree model. In addition, univariate sensitivity analysis and probabilistic sensitivity analysis were performed. RESULTS Meta-analysis showed that esomeprazole triple therapy was slightly superior to omeprazole triple therapy in terms of efficacy(eradication rates: RR=0.93,P=0.03) and there was no significant difference between the two therapies. pharmacoeconomics evaluation results show that compared to omeprazole triple therapy, The ICER value of esomeprazole triple therapy was 2609.00 yuan, and the sensitivity analysis results were roughly consistent with the basic analysis results, indicating that the basic analysis results were relatively robust. CONCLUSION Esomeprazole triple therapy is slightly superior to omeprazole triple therapy in the treatment of peptic ulcer, however, the ICER of esomeprazole triple therapy is much higher compared to omeprazole triple therapy, so omeprazole triple therapy is more economical for the treatment of peptic ulcer.
作者
管欣
李洪超
邵荣杰
何玉梅
马爱霞
GUAN Xin;LI Hong-chao;SHAO Rong-jie;HE Yu-mei;MA Ai-xia(China Pharmaceutical University School of International Pharmaceutical Business,Jiangsu Nanjing 211198,China)
出处
《中国医院药学杂志》
CAS
北大核心
2019年第5期502-507,共6页
Chinese Journal of Hospital Pharmacy
基金
江苏省教育厅哲学社会科学基金(编号:2016SJD630007)
